Publications

Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B.

Author(s): Li X,  Li H,  Li S,  Zhu F,  Kim DJ,  Xie H,  Li Y,  Nadas J,  Oi N,  Zykova TA,  Yu DH,  Lee MH,  Kim MO,  Wang L,  Ma W,  Lubet RA,  Bode AM,  Dong Z,  Dong Z

Journal: Carcinogenesis

Date: 2012 Dec

Major Program(s) or Research Group(s): CADRG

PubMed ID: 22962305

PMC ID: PMC3510736

Abstract: Ceftriaxone, an FDA-approved third-generation cephalosporin antibiotic, has antimicrobial activity against both gram-positive and gram-negative organisms. Generally, ceftriaxone is used for a variety of infections such as community-acquired pneumonia, meningitis and gonorrhea. Its primary molecular targets are the penicillin-binding proteins. However, other activities of ceftriaxone remain unknown. Herein, we report for the first time that ceftriaxone has antitumor activity in vitro and in vivo. Kinase profiling results predicted that Aurora B might be a potential 'off' target of ceftriaxone. Pull-down assay data confirmed that ceftriaxone could bind with Aurora B in vitro and in A549 cells. Furthermore, ceftriaxone (500 µM) suppressed anchorage-independent cell growth by targeting Aurora B in A549, H520 and H1650 lung cancer cells. Importantly, in vivo xenograft animal model results showed that ceftriaxone effectively suppressed A549 and H520 lung tumor growth by inhibiting Aurora B. These data suggest the anticancer efficacy of ceftriaxone for the treatment of lung cancers through its inhibition of Aurora B.